Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

"A little bit of masking tape and a lot of glitter": Perspectives of older LGBT+ Australians on navigating aged care.

Geriatric nursing (New York, N.Y.)·2026
Same author

Aged and Health Care Service Use by Older Australians Who Identify as Lesbian, Gay, Bisexual, Transgender, Intersex or Gender Diverse: A Retrospective Cohort Study.

Journal of homosexuality·2026
Same author

Manual wheelchair training for individuals with chronic and progressive conditions: a critical realist approach to improving practice.

BMC health services research·2025
Same author

Drug Development.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)·2025
Same author

Using Nominal Group Technique to Gather Recommendations in the Decision-Making for Amputation Due to Diabetes.

Journal of foot and ankle research·2025
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Coco Kusiak1, Rachel Mak-McCully1, Carolyn Murray1

  • 1Unlearn.AI, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los gemelos digitales pueden reducir el tamaño de la muestra en ensayos de enfermedad de Alzheimer hasta en un 24% o aumentar la potencia para puntos finales secundarios. Este enfoque mejora la eficiencia estadística en ensayos clínicos para tratamientos como el donanemab.

Palabras clave:
gemelos digitalesensayos clínicosAlzheimerdonanemabeficiencia estadística

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurociencia
  • Ensayos Clínicos
  • Bioestadística

Sus antecedentes:

  • El ensayo TRAILBLAZER-ALZ 2 demostró que el donanemab reducía eficazmente las placas de amiloide y ralentizaba el deterioro cognitivo en la enfermedad de Alzheimer temprana.
  • Sin embargo, los puntos finales secundarios y los análisis de subgrupos carecían de potencia suficiente.
  • Las covariables pronósticas, como los gemelos digitales, pueden mejorar la potencia estadística y reducir los requisitos de tamaño de muestra.

Objetivo del estudio:

  • Simular el ensayo TRAILBLAZER-ALZ 2 y cuantificar la reducción del tamaño de la muestra o la ganancia de potencia al incorporar gemelos digitales de los participantes.
  • Evaluar el impacto de los gemelos digitales en el análisis estadístico de los datos de ensayos clínicos de la enfermedad de Alzheimer.

Principales métodos:

  • Se creó un conjunto de datos sintético que reflejaba la cohorte TRAILBLAZER-ALZ 2, con participantes aleatorizados 1:1.
  • Se simularon los efectos del tratamiento con donanemab.
  • Se generaron gemelos digitales de los participantes utilizando el Generador de Gemelos Digitales para la Enfermedad de Alzheimer de Unlearn.

Principales resultados:

  • La incorporación de gemelos digitales como covariables podría haber reducido el brazo de control del ensayo TRAILBLAZER-ALZ 2 hasta en un 24% para el resultado primario (iADRS a los 18 meses).
  • Los gemelos digitales podrían aumentar la potencia estadística para los puntos finales secundarios hasta en un 15%.
  • Los análisis de subgrupos también demostraron una mayor potencia.

Conclusiones:

  • Los gemelos digitales, cuando se utilizan como supercovariables, pueden reducir significativamente el tamaño de la muestra o mejorar la potencia en ensayos clínicos de la enfermedad de Alzheimer.
  • Este método mejora la eficiencia del análisis de los puntos finales primarios, secundarios y de subgrupos.
  • Los gemelos digitales ofrecen una herramienta valiosa para optimizar el diseño y el análisis de ensayos clínicos en la investigación de la enfermedad de Alzheimer.